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Background: Idiopathic pulmonary fibrosis (IPF) is a progressive lung disease with poor prognosis. The kinase
inhibitor nintedanib specific for vascular endothelial growth factor receptor (VEGFR), platelet-derived growth factor
receptor (PDGFR) and fibroblast growth factor receptor (FGFR) significantly reduced the rate of decline of forced
vital capacity versus placebo.
Aim: To determine the in vitro effect of nintedanib on primary human lung fibroblasts. Methods: Fibroblasts were
isolated from lungs of IPF patients and from non-fibrotic controls. We assessed the effect of VEGF, PDGF-BB and
basic FGF (bFGF) ± nintedanib on: (i) expression/activation of VEGFR, PDGFR, and FGFR, (ii) cell proliferation, secretion
of (iii) matrix metalloproteinases (MMP), (iv) tissue inhibitor of metalloproteinase (TIMP), and (v) collagen.
Results: IPF fibroblasts expressed higher levels of PDGFR and FGFR than controls. PDGF-BB, bFGF, and VEGF caused a
pro-proliferative effect which was prevented by nintedanib. Nintedanib enhanced the expression of pro-MMP-2, and
inhibited the expression of TIMP-2. Transforming growth factor-beta-induced secretion of collagens was inhibited by
nintedanib.
Conclusion: Our data demonstrate a significant anti-fibrotic effect of nintedanib in IPF fibroblasts. This effect consists
of the drug’s anti-proliferative capacity, and on its effect on the extracellular matrix, the degradation of which seems to
be enhanced.
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Idiopathic pulmonary fibrosis (IPF) is the most common
form of idiopathic interstitial pneumonias, and it is char-
acterized by a progressive decline in lung function, poor
survival and limited therapeutic options. The pathogenesis
remains incompletely understood, but aberrant wound
healing, resulting in progressive lung injury and scarring
seem to play a pivotal role [1].
It is indicated that fibroblasts play a central role in the
pathogenesis of fibrotic processes, and several factors in-
fluence their proliferation and extracellular matrix (ECM)* Correspondence: katrin.hostettler@usb.ch
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unless otherwise stated.synthesis [1]. In IPF, these mesenchymal cells have an in-
creased activity and response to fibrogenic cytokines [1].
Several growth factors are suggested to be pivotal in the
development of IPF, including platelet-derived growth fac-
tor (PDGF), basic fibroblast growth factor (bFGF), and
vascular endothelial growth factor (VEGF). PDGF is a
fibrogenic mediator [2], and was increased in a murine
IPF-animal model [3]. The inhibition of PDGF signalling
reduced bleomycin-induced pulmonary fibrosis in mice
[4]. bFGF is a potent mitogenic factor and high levels of
bFGF were found in lung tissue derived from patients with
IPF [5]. And finally, blocking VEGF signalling reduced
lung fibrosis in a mouse model [6].
Nintedanib (BIBF 1120) is an orally available indolinone
derivate that competitively binds to the ATP-binding sites
within the kinase domains of VEGF receptor (VEGFR)1,ral. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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PDGF receptor (PDGFR)α and PDGFRβ [7]. In vitro data
demonstrated direct growth inhibitory activity of ninteda-
nib in different cell lines [7].
Two randomized, placebo controlled, phase 3 trials
(INPULSIS-1 and INPULSIS-2) evaluating the efficacy
and safety of nintedanib in patients with IPF demonstrated
that nintedanib-treatment reduced the decline in forced
vital capacity, which conforms to a slow-down of disease
progression [8]. Furthermore, in one trial (INPULSIS-2),
there was a significant benefit with nintedanib versus
placebo with regard to the time to the first acute ex-
acerbation [8].
So far, the effect of nintedanib on primary human lung
cells derived from patients with IPF has not been ex-
plored. In the present study, we determined the in vitro
effect of nintedanib on the proliferative capacity and
collagen synthesis by primary human lung fibroblasts de-
rived from IPF lungs and non-fibrotic controls.
Materials and methods
Nintedanib (BIBF 1120) ((methyl (3Z)-3-[({4-[N-methyl-
2-(4-methylpiperazin-1-yl)acetamido]phenyl}amino)(phenyl)
methylidene]-2-oxo-2,3-dihydro-1H-indole-6-carboxylate
ethane sulfonate salt, batch # 1051764) was provided
by Boehringer Ingelheim Pharma GmbH & Co. KG,
Biberach, Germany.
Patients and cell culture
Human lung tissue was obtained with the approval of
the Human Ethics Committee of the University of Basel
(Ref. Nr. EK:05/06), Switzerland, and with the written in-
formed consent of each patient. Human primary lung
cells were isolated, as reported previously [9], from lung
biopsies of 4 patients diagnosed with IPF according to
the recently published guidelines [10]. Non-fibrotic con-
trol cells were isolated from the macroscopically normal
part of the lung of 4 patients undergoing therapeutic
lung resection for carcinoma. All experiments were per-
formed using cells at passage 3 to 6.
Western blotting
IPF fibroblasts and non-fibrotic control cells were grown
to 80% confluence and were then serum-starved for
24 hours. Cells were pre-incubated for 30 minutes with
nintedanib (400 nM) before different stimuli (recombinant
human PDGF-BB [10 ng/ml], recombinant human bFGF
[10 ng/ml], recombinant human VEGF [10 ng/ml]: R&D
Systems; Abingdon, United Kingdom) were added for an-
other 30 minutes. Western blotting was performed as pre-
viously described [11]. Primary antibodies used: PDGFRα,
VEGFR1, FGFR1, c-Abelson (c-Abl), extracellular signal-
regulated kinase (ERK) 1/2, phosphorylated (pho) PDGFRα/
β, pho-VEGFR2, pho-c-Abl, pho-ERK1/2 (Cell SignalingTechnology, BioConcept; Allschwil, Switzerland) and pho-
FGFR1α (Abcam; Cambridge, United Kingdom).
Cell proliferation
Cells were seeded (104 cells/ml) in 24-well plates and
allowed to attach overnight before being serum starved
(0.1% FCS, 24 hours). Cells were then exposed to differ-
ent stimuli (recombinant human PDGF-BB [R&D Systems];
recombinant human bFGF [R&D Systems]; recombinant
human VEGF [R&D Systems]) in the presence and absence
of nintedanib (0.001, 0.01, 0.1, 1 μM) for 48 hours before
being manually counted (Neubauer hematocytometer).
Gelatin zymography
Confluent serum-deprived fibroblasts were stimulated with
increasing concentrations of nintedanib (0.001, 0.01, 0.1,
1 μM) under standard conditions for 24 hours, and condi-
tioned medium samples were collected. The gelatinolytic
activity of matrix metalloproteinase (MMP)-2 and −9 was
determined as described earlier [12].
Enzyme-linked immunosorbent assay
Concentrations of MMP-2 and tissue inhibitor of metal-
loproteinase (TIMP)-2 were quantified in the condi-
tioned medium using an enzyme-linked immunosorbent
assay (ELISA) kit (R&D Systems). Sensitivity of the method
employed was: MMP − 2: 0.16 ng/ml and TIMP-2:
0.011 ng/ml.
ECM-deposition
Confluent serum-deprived fibroblasts were stimulated
with 5 ng/ml human recombinant transforming growth
factor-β (TGF-β) 1 (R&D Systems) and incubated in the
presence or absence of nintedanib (0.001, 0.01, 0.1,
1 μM). The cells were further kept under standard
conditions (37°C, 95% humidity, 5% CO2) for 48 hours.
Collagen secretion and deposition (collagens type I to V)
were determined using Sircol™ Assay kit (Biocolor;
Carrickfergus, United Kingdom).
Statistical analysis
Statistical comparisons were made by Student’s t-test.
p-values ≤ 0.05 were considered significant. Where applic-
able, data are shown as mean ± standard error of the mean
(SEM) from at least three independent experiments per-
formed in duplicates or triplicates. Data representing image
analysis are shown as representative immunoblots and as
means SEM after densitometric image analysis.
Results
The effect of nintedanib on receptor expression and
phosphorylation
The viability of fibroblasts was not affected by the treat-
ment with nintedanib at concentrations up to 1 μM as
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There was no difference comparing the effect of ninteda-
nib on viability in IPF cells versus non-fibrotic control cells
(data not shown). IPF fibroblasts expressed higher levels
of PDGFR and FGFR, as compared to non-fibrotic control
cells (Figure 1B), whereas VEGFR was expressed at similar
levels in fibrotic and non-fibrotic cells (Figure 1B). A sig-
nificant inhibitory effect of nintedanib on phosphoryl-
ation of growth factor receptors by their specific ligands
was observed for the PDGFR and the VEGFR in IPF cells
(Figure 1C). High levels of phosphorylated FGFR were
found in unstimulated cells which could not be further en-
hanced by stimulation with bFGF, but a down-regulation
was detected in the presence of nintedanib in IPF cells
(Figure 1C).
Nintedanib inhibits growth-factor-induced proliferation of
primary human lung fibroblasts
We observed a significant pro-proliferative effect of PDGF-
BB (p < 0.05, Figure 2A,) and bFGF (p < 0.05, Figure 2C,)
in primary IPF lung fibroblasts, as well as in cells from
non-fibrotic control lungs (p < 0.05, Figure 2B [PDGF-BB];Figure 1 Effect of nintedanib on receptor expression and phosphoryl
increasing concentrations of nintedanib (0.01, 0.1, and 1 μM) for 24 hours
(B) Representative immuno-blots showing the expression of total PDGF
in primary human lung IPF fibroblasts and non-fibrotic control cells. The bar c
normalised to GAPDH in IPF and control cells. Data are presented as mean ±
(C) Representative immuno-blots showing total and phosphorylated PDGFR,
starved for 24 hours. Before stimulation with PDGF-BB, bFGF, or VEGF (all 10 n
for 30 minutes. The bar charts summarise the densitometric analysis of recept
Data are presented as mean ± SEM of experiment performed in three differenp < 0.05, Figure 2D [bFGF]). The pro-proliferative effect
induced by the two growth factors was significantly more
pronounced in non-fibrotic control cells compared to IPF
fibroblasts. VEGF also caused a significant mitogenic ef-
fect in non-fibrotic cells (p < 0.05, Figure 2F), but not in
IPF-derived fibroblasts (Figure 2E). In IPF fibroblasts,
the mitogenic effect induced by PDGF-BB (10 ng/ml)
was significantly prevented by pre-incubation (30 minutes)
with nintedanib, at concentrations of 0.1 μM (p < 0.05;
Figure 2A) and 1 μM (p < 0.05; Figure 2A). In non-fibrotic
cells, even lower concentrations of nintedanib (0.001 μM,
0.01 μM) significantly antagonized the PDGF-BB-induced
pro-proliferative effect (p < 0.05; Figure 2B). Similar re-
sults were obtained in bFGF-stimulated fibroblasts. As
shown in Figure 2C, nintedanib significantly prevented
the bFGF-induced pro-proliferative effect in IPF fibro-
blasts at concentrations of 0.01, 0.1, and 1 μM (p < 0.05;
Figure 2C). In non-fibrotic fibroblasts, even the lowest
concentration of nintedanib (0.001 μM) prevented the
bFGF-induced proliferation (p < 0.05; Figure 2D). In IPF
fibroblasts, VEGF-induced proliferation was very low,
as compared to PDGF-BB or bFGF-induced effects.ation. (A) Fibroblasts derived from patients with IPF were treated with
and cell viability was analysed by trypan blue exclusion staining.
-receptor (PDGFR), VEGF-receptor (VEGFR) and FGF-receptor (FGFR),
harts summarise the densitometric analysis of total receptor expression
SEM of experiment performed in three different cell lines. *p < 0.05.
VEGFR, and FGFR in primary human lung IPF fibroblasts. Fibroblasts were
g/ml) for 30 minutes, cells were pre-incubated with nintedanib (400 nM)
or phosphorylation normalised to total receptor expression in IPF cells.
t cell lines. *p < 0.05.
Figure 2 Effect of nintedanib on PDGF-BB- (A, B), bFGF- (C, D), and VEGF- (E, F) induced fibroblast proliferation compared with
serum-free RPMI (control) in fibroblasts derived from IPF lungs (A, C, E) and non-fibrotic control lungs (B, D, F). Primary human
lung fibroblasts derived from IPF patients and from non-fibrotic lungs were pre-incubated for 30 minutes with increasing concentrations of
nintedanib (0.001, 0.01, 0.1, and 1 μM), before adding PDGF-BB (10 ng/ml), bFGF (10 ng/ml), and VEGF (10 ng/ml) for 48 hours. Serum-free
RPMI served as control. Cell growth was assessed by manual cell counting, and values are presented as mean ± SEM of triplicate independent
experiments performed in 4 different cell lines, expressed as relative proliferation compared to control (serum-free RPMI medium) which
was set to 100%. *p < 0.05.
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at the highest concentration of 1 μM (p < 0.05; Figure 2E).
Even more in non-fibrotic fibroblasts nintedanib com-
pletely prevented VEGF-induced proliferation already
at a very low concentration of 0.001 μM (p < 0.05;
Figure 2F).Effect of nintedanib on matrix metalloproteinases and
their inhibitors
In IPF fibroblasts the activity of pro-MMP-2 was signifi-
cantly induced by nintedanib (0.001, 0.01, 0.1, 1 μM), as
demonstrated by gelatin zymography (p < 0.05; Figure 3A
and C). Similarly, in non-fibrotic control cells nintedanib
Figure 3 Effect of nintedanib on enzymatic activity (panel A-D) and secretion of matrix metalloproteinase (MMP)-2 (panel E, F) and tissue
inhibitor of metalloproteinase (TIMP)-2 (panel G, H) by primary human lung IPF fibroblasts (A, C, E, G) and by non-fibrotic control cells
(B, D, F, H). Fibroblasts were treated with increasing concentrations of nintedanib (0.001, 0.01, 0.1, and 1 μM) for 24 hours and conditioned cell
medium was collected. (A, B) Representative gelatine-based zymograms of the effect of nintedanib on pro-MMP-2 enzymatic activity by IPF
fibroblasts (A) and by control cells (B). Arrows indicate the migration position of purified pro-MMP-2. (C, D) Densitometric analysis of pro-MMP-2
enzymatic activity in primary human lung fibroblasts obtained from IPF lungs (C), and from non-fibrotic controls (D). Values are presented
as mean ± SEM of independent experiments performed in 4 different cell lines, expressed as percentage of control (serum-free RPMI medium).
Each experiment was performed at least in duplicates. *p < 0.05. The effect of nintedanib on the secretion of MMP-2 and TIMP-2 by IPF fibroblasts
(E, G) and control cells (F, H) was assessed by ELISA. Values are presented as mean ± SEM of independent experiments performed in 4 different cell
lines, expressed as percentage of control (serum-free RPMI medium). Each experiment was performed at least in duplicates. *p < 0.05.
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(p < 0.05; Figure 3B and D). Only minor amounts of pro-
MMP-9 were detected (data not shown). Gelatin zymo-
graphy data for pro-MMP-2 were confirmed by ELISA
(p < 0.05; Figure 3E and F). Finally, IPF fibroblasts, as well
as non-fibrotic control cells secreted TIMP-2 protein,
which was reduced by nintedanib (1 μM) (Figure 3G,H).
Growth-factor-induced collagen secretion is inhibited by
nintedanib
None of the three growth factors significantly enhanced
collagen secretion of primary human lung fibroblasts (data
not shown). In contrast, TGF-β1 (5 ng/ml) significantly
increased collagen secretion in IPF fibroblasts (p < 0.05;
Figure 4A) and in non-fibrotic control cells (p < 0.05;
Figure 4B). High concentrations of nintedanib (1 μM)
significantly prevented TGF-β-induced collagen secretion
from IPF fibroblasts (p < 0.05; Figure 4A), as well as in
control cells (p ≤ 0.05; Figure 4B). Equally, in IPF fibro-
blasts the deposition of collagens was significantly induced
by TGF- β1 (5 ng/ml), and this was prevented by 1 μM
of nintedanib (p < 0.05; Figure 4C). In control cells, the
TGF-β-induced collagen deposition was very low and no
significant effect of nintedanib was observed (data notFigure 4 Effect of nintedanib on TGF-β-induced secretion (panel A, B)
IPF fibroblasts (panel A, C) and by non-fibrotic control cells (B). Prima
nintedanib (0.001, 0.01, 0.1, and 1 μM), before adding TGF-β (5 ng/ml)
by the Sircol™ Assay, and values are presented as mean ± SEM of indep
as percentage of control (0.1% FCS) which was set to 100%. Each experim
immuno-blots showing the expression of total and phosphorylated ERK1/2 an
for 24 hours. Before stimulation with TGF-β1 (5 ng/ml) for 5 minutes, cells we
summarise the densitometric analysis of receptor phosphorylation normalised
presented as mean ± SEM of experiment performed in three different cshown). Protein analysis demonstrated an inhibitory effect
of nintedanib (1 μM) on TGF-β1-induced phosphorylation
of the mitogen-activated protein (MAP) kinase ERK1/2
and the protein tyrosine kinase c-Abl (Figure 4D). No
phosphorylation of Smad2/3 was observed upon TGF-β
stimulation (data not shown).
Discussion
In this study we investigated the in vitro effect of ninteda-
nib on the proliferative capacity as well as on the extracel-
lular matrix metabolism of primary human lung fibroblasts
obtained from patients with IPF and from non-fibrotic
control lungs. We found that the receptor tyrosine kinase
inhibitor nintedanib prevented growth-factor induced pro-
liferation of both IPF and control fibroblasts. Furthermore,
growth-factor induced collagen synthesis was significantly
reduced by nintedanib. Interestingly, the drug up-regulated
pro-MMP-2 secretion, but down-regulated its inhibitor
TIMP-2.
IPF is a progressive lung disease with a median survival
time after diagnosis of 2.5 to 3.5 years [13], and limited
therapeutic options. The pathomechanisms that lead to
IPF are not fully understood, however, they ultimately re-
sult in enhanced numbers of mesenchymal cells and theand deposition (panel C) of collagens by primary human lung
ry human lung fibroblasts were pre-incubated for 30 minutes with
for 48 hours. Collagen secretion and deposition were quantitated
endent experiments performed in 4 different cell lines, expressed
ent was performed at least in duplicates. *p < 0.05. (D) Representative
d c-Abl in primary human lung IPF fibroblasts. Fibroblasts were starved
re pre-incubated with nintedanib (1 μM) for 30 minutes. The bar charts
to α–tubulin and total receptor expression in IPF cells. Data are
ell lines. *p < 0.05.
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Nintedanib, an intracellular inhibitor of tyrosine kinases,
has proven good antitumor/antiproliferative efficacy [7],
and had beneficial effects in patients with IPF [8]. Ninteda-
nib’s targets include PDGFR, FGFR, and VEGFR [7], which
have been shown to be involved in lung fibrosis [4,6,14].
Using primary human lung fibroblasts obtained from IPF
lungs and from non-fibrotic control lungs, we found that IPF
cells expressed higher levels of PDGFR and FGFR compared
to controls. This finding is in line with previous data showing
an enhanced expression of FGFR1 on myofibroblast-like cells
in IPF patients [5], and up-regulated PDGFRα expression
in a rodent model of lung fibrosis [15]. Whereas we found
similar levels of VEGFR in fibrotic and non-fibrotic cells,
others reported an increased expression of VEGFR1 in
IPF patients [16]. However, in the latter study soluble
VEGFR was measured in bronchoalveolar lavage fluid,
whereas we used protein extracts from pure primary hu-
man lung fibroblasts, which makes it difficult to compare
the data.
PDGF-BB and bFGF are potent mitogenic and chemo-
tactic factors for mesenchymal cells [2,5] and both fac-
tors were shown to be elevated in IPF patients [5,17].
Accordingly, we observed a strong mitogenic effect of
PDGF-BB and bFGF in primary human lung fibroblasts
from IPF and non-fibrotic control lungs. Importantly,
the observed mitogenic effect was stronger in the con-
trol cells than in IPF cells (2-fold for PDGF-BB, 1.7-fold
for bFGF), which is in line with previous data demon-
strating a different response to growth factors by normal
and IPF fibroblasts [18]. VEGF is an important regulator
of neovascularization [19], and recent data supported
the hypothesis that it might be involved in fibrotic dis-
eases [20]. In this regard, marked vascular changes were
reported in an animal model of lung fibrosis [21]. Cur-
rently, the role of VEGF in IPF is not clear, since VEGF
plasma levels were significantly related to radiologic
fibrosis scores in patients with idiopathic interstitial pneu-
monias [20], but decreased VEGF levels in broncho-
alveolar lavage fluid from patients with IPF have been
reported [22]. Even though VEGF is considered to be a
specific mitogen for endothelial cells, we observed a mito-
genic effect of VEGF in IPF, as well as in non-fibrotic con-
trol fibroblasts, reaching statistical significance only in the
latter ones.
In accordance with previous data [7], nintedanib inhib-
ited the PDGF-, FGF-, and VEGF-induced fibroblast pro-
liferation in a concentration dependent manner in IPF as
well as in non-fibrotic control cells. In our primary human
fibroblasts, we observed that the antagonistic capacity
of nintedanib was significantly stronger in non-fibrotic
cells compared to IPF fibroblasts. This reduced sensi-
tivity of IPF cells towards nintedanib might be explained
by the higher PDGFR and FGFR expression in IPF cells.Furthermore, in contrast to our findings on collagen se-
cretion, where only high concentrations of nintedanib pre-
vented growth-factor induced collagen secretion, cell
proliferation was potently inhibited by low concentrations
of nintedanib.
The excessive accumulation of ECM is a hallmark of
IPF [1], and therefore we studied the effect of nintedanib
on ECM metabolism. We found that nintedanib induced
the activity and protein levels of MMP-2, and reduced
the levels of TIMP-2. MMPs are a family of secreted
zinc-containing endopeptidases that degrade proteins of
the ECM, and TIMP are their main physiological inhibi-
tors [23]. Both MMP-2 and MMP-9 metabolize various
ECM proteins including type IV and type V collagens and
gelatin [23]. MMPs are secreted as inactive precursors
which have to be activated in the extracellular space.
MMP-2 can be activated by type I collagen and thrombin
[24,25], but also by a membrane-type MMP-dependent
pathway involving TIMP-2 [11]. An imbalance between
MMP and TIMP might be involved in the accumulation
of ECM in fibrogenesis [26]. Accordingly, a greater in-
crease in the levels of TIMP than levels of MMP-2 was re-
ported and such an imbalance would favour the enhanced
deposition of ECM proteins [27]. Interestingly, TGF-β in-
duced lung fibrosis in mice was primarily due to TIMP
up-regulation [28], and a recent study demonstrated that
over-expression of MMP-9 by alveolar macrophages in
mice attenuated the fibrotic reaction after bleomycin in-
stillation [29]. Therefore, if TIMP are elevated in IPF, a
drug that reduces the secretion of TIMP-2 by fibroblasts
is possibly a powerful tool in the therapy of this devastat-
ing disease.
To further investigate nintedanib’s anti-fibrotic poten-
tial, we determined the drug’s effect on PDGF-, FGF-,
and VEGF-induced collagen secretion. Similar to others
we observed no significant modulation of collagen secre-
tion upon stimulation with the three growth-factors in
fibroblasts [30,31].
TGF-β is a well-known stimulator of collagen production,
a pivotal mediator of fibrogenesis, and TGF-β-induced dis-
turbances are critical in IPF [32,33]. As expected, TGF-β
up-regulated total collagens in IPF and control fibroblasts,
and this effect was antagonized by the highest concentra-
tion of nintedanib (1 μM). To elucidate the underlying
mechanism of this effect, several down-stream signalling
pathways of TGF-β were studied. It could be demon-
strated that nintedanib inhibited TGF-β1-induced phos-
phorylation of the MAP kinase ERK1/2 and of the protein
tyrosine kinase c-Abl. The lack of phosphorylation of
Smad2/3 upon TGF-β stimulation in primary human lung
fibroblasts is in accordance with previous data [34]. The
finding that TGF-β stimulates c-Abl tyrosine kinase is in
line with others identifying c-Abl as an important elem-
ent of TGF-β signalling and crucial for TGF-β-induced
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component of the non-canonical TGF-β-signalling [36]
and inhibition of ERK suppressed collagen expression
in vitro [37]. Based on our data we therefore suggest that
the antagonistic effect of nintedanib on TGF-β-induced
collagen secretion is – at least partly – due to the inhib-
ition of c-Abl and/or ERK1/2. We hypothesize that the
kinase inhibitor nintedanib inhibits c-Abl tyrosine kinase,
similar to imatinib mesylate, a tyrosine kinase inhibitor
specific for PDGFR as well as cAbl [35,38]. Finally, the
ERK1/2 MAP kinase is not TGF-β-specific but is also a
downstream target responsive to PDGF receptor activa-
tion [39]. In summary, our data indicate that nintedanib is
not only able to inhibit the pro-fibrotic effects of PDGF
and FGF but is also capable of abrogating the effects of
TGF-β – a key mediator in tissue fibrogenesis.
Our study has several limitations: i) we are aware that
alveolar epithelial cells are thought to be critical in the
initiation and progression of the fibrotic process in IPF
[1]. However, the growth factor-induced proliferation of
local fibroblasts and the exaggerated accumulation of
fibroblast-derived ECM ultimately result in the destruc-
tion of the lung parenchyma. Therefore, we feel that
studying the effect of nintedanib on fibroblasts is justi-
fied; ii) we acknowledge that measuring pro-MMPs is
not reflecting their bioactivity which requires the inter-
action with other cell types.
Conclusions
To the best of our knowledge this is the first study to in-
vestigate the effect of nintedanib in primary human lung
cells obtained from IPF patients. Our in vitro data demon-
strate a significant anti-fibrotic effect of nintedanib in pri-
mary human lung fibroblasts derived from patients with
IPF. This effect consists of the drug’s anti-proliferative ef-
fect, as well as its effect on the ECM, the degradation of
which seems to be enhanced. The combined anti-fibrotic
activities of nintedanib may impact the progressive course
of fibrotic lung diseases like IPF.
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